Journals / The Anatolian Journal of Cardiology / 2019 / Cilt: 21 - Sayı: 6

Experience of left atrial appendage occlusion with the WATCHMAN device in Chinese patients

Pages
314–321
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Most of the target population had increased bleeding risk or non-compliance for OAC as indications and received OAC for antithrombotic therapy after the procedure. (Anatol J Cardiol 2019; 21: 314-21)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Little is known about left atrial appendage occlusion (LAAO) with WATCHMAN device in patients with atrial fibrillation (AF) in China.The aim of the present study was to evaluate the acute procedural performance and complication rate of LAAO procedures and patient selection in China.Methods: A total of 658 consecutive Chinese patients who were referred to receive LAAO procedures with the WATCHMAN device between 2014 and 2017 were retrospectively included in the study.
📊
Key Findings & Data:Patients were divided into four groups according to the year of procedures: Group 2014, Group 2015, Group 2016, and Group 2017.
💡
Conclusion & Impact:Most of the target population had increased bleeding risk or non-compliance for OAC as indications and received OAC for antithrombotic therapy after the procedure. (Anatol J Cardiol 2019; 21: 314-21)
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: Little is known about left atrial appendage occlusion (LAAO) with WATCHMAN device in patients with atrial fibrillation (AF) in China.The aim of the present study was to evaluate the acute procedural performance and complication rate of LAAO procedures and patient selection in China.Methods: A total of 658 consecutive Chinese patients who were referred to receive LAAO procedures with the WATCHMAN device between 2014 and 2017 were retrospectively included in the study. Patients were divided into four groups according to the year of procedures: Group 2014, Group 2015, Group 2016, and Group 2017. The procedural success, complication rates, and characteristics of Chinese patients, as well as the trends of patients’ selection and management, were analyzed.Results: The average age of the patients was 67.7±9.2 years, the CHA2DS2 -VASc score was 3.7±1.6, and the HAS-BLED score was 2.5±1.1. Bothscores of patients in different years show obvious increasing trends (r=0.126, p=0.001 and r=0.145, p<0.001, respectively). Indications for LAAO included increased bleeding risk (45.6%), recent bleeding under oral anticoagulation (OAC) (9.0%), and non-compliance with OAC (51.4%). The implantation was successful in 643 (97.7%) patients, with a procedural complication rate of 0.6%. Approximately 80.1% of the patients received OAC after LAAO.Conclusion: In China, LAAO with WATCHMAN devices in patients with AF can be performed successfully with a low complication rate. Most of the target population had increased bleeding risk or non-compliance for OAC as indications and received OAC for antithrombotic therapy after the procedure. (Anatol J Cardiol 2019; 21: 314-21)

🔖

Cite This Article

ZHAI, Z., TANG, M., SU, X., CHU, H., HUANG, W., ZENG, J., WANG, J., FANG, P., YIN, X., MA, G., ZHAO, S., ZHANG, S. (2019). Experience of left atrial appendage occlusion with the WATCHMAN device in Chinese patients. The Anatolian Journal of Cardiology, Cilt: 21 - Sayı: 6, 314–321. https://ajindex.com/articles/365278

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Tse HF, Wang YJ, Ahmed Ai-Abdullah M, Pizarro-Borromeo AB, Chiang CE, Krittayaphong R, et al. Stroke prevention in atrial fibrillation- -an Asian stroke perspective. Heart Rhythm 2013; 10: 1082-8
  2. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012; 14: 528-606
  3. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903-12
  4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51
  5. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014; 129: 1568-76
  6. Chang SS, Dong JZ, Ma CS, Du X, Wu JH, Tang RB, et al. Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study. Stroke 2016; 47: 1803-10
  7. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61: 755-9
  8. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol 2017; 70: 2964-75
  9. Holmes DR Jr, Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level MetaAnalysis. J Am Coll Cardiol 2015; 65: 2614-23
  10. Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014; 6